Syndax Pharmaceuticals (SNDX) Competitors $8.82 -0.54 (-5.77%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$8.90 +0.08 (+0.91%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX vs. AAPG, SRRK, MTSR, KYMR, VKTX, MOR, CRNX, ALVO, MLTX, and CPRXShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), MoonLake Immunotherapeutics (MLTX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Its Competitors Ascentage Pharma Group International Scholar Rock Metsera Kymera Therapeutics Viking Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech MoonLake Immunotherapeutics Catalyst Pharmaceuticals Syndax Pharmaceuticals (NASDAQ:SNDX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Is SNDX or AAPG more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -757.53%. Ascentage Pharma Group International's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax Pharmaceuticals-757.53% -101.60% -58.41% Ascentage Pharma Group International N/A N/A N/A Which has stronger earnings and valuation, SNDX or AAPG? Ascentage Pharma Group International has higher revenue and earnings than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M32.05-$318.76M-$3.86-2.28Ascentage Pharma Group International$134.35M25.28-$55.54MN/AN/A Does the media favor SNDX or AAPG? In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Syndax Pharmaceuticals and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.11 beat Syndax Pharmaceuticals' score of 0.25 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascentage Pharma Group International 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend SNDX or AAPG? Syndax Pharmaceuticals currently has a consensus target price of $35.80, indicating a potential upside of 305.90%. Given Syndax Pharmaceuticals' higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAscentage Pharma Group International beats Syndax Pharmaceuticals on 7 of the 11 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$805.83M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-2.2821.1726.2119.74Price / Sales32.05262.85395.51109.12Price / CashN/A41.8936.4957.06Price / Book2.617.237.915.37Net Income-$318.76M-$55.05M$3.15B$248.34M7 Day Performance-0.90%-0.60%0.77%1.67%1 Month Performance-19.67%3.77%3.46%4.56%1 Year Performance-57.31%2.20%34.61%18.42% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals3.0909 of 5 stars$8.82-5.8%$35.80+305.9%-59.0%$805.83M$23.68M-2.28110Positive NewsAAPGAscentage Pharma Group InternationalN/A$37.15-0.6%N/AN/A$3.26B$134.35M0.00600Positive NewsSRRKScholar Rock4.1162 of 5 stars$33.28-2.2%$42.67+28.2%+315.3%$3.23B$33.19M-13.15140MTSRMetseraN/A$29.00-2.0%$55.00+89.7%N/A$3.11BN/A0.0081Gap DownKYMRKymera Therapeutics3.0889 of 5 stars$46.29+0.9%$59.82+29.2%+43.6%$2.99B$47.07M-14.93170Trending NewsInsider TradeAnalyst RevisionVKTXViking Therapeutics4.1532 of 5 stars$24.86-4.4%$87.15+250.6%-51.8%$2.92BN/A-21.6220Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.5618 of 5 stars$29.91-0.8%$74.56+149.3%-38.3%$2.82B$1.04M-7.83210ALVOAlvotech3.7277 of 5 stars$9.13-2.4%$18.00+97.2%-26.6%$2.82B$491.98M24.681,032MLTXMoonLake Immunotherapeutics2.2733 of 5 stars$44.87+3.1%$78.71+75.4%+11.5%$2.78BN/A-19.512CPRXCatalyst Pharmaceuticals4.9337 of 5 stars$22.12-1.6%$32.83+48.4%+34.4%$2.74B$491.73M14.0980Positive News Related Companies and Tools Related Companies AAPG Alternatives SRRK Alternatives MTSR Alternatives KYMR Alternatives VKTX Alternatives MOR Alternatives CRNX Alternatives ALVO Alternatives MLTX Alternatives CPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNDX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
